Treatment Shortening of MDR-TB Using Existing and New Drugs
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of a 'new treatment regimen including
delamanid, linezolid, levofloxacin, and pyrazinamide for nine or twelve months
(investigational arm)' and 'the standard treatment regimen including injectables for 20 to 24
months (control arm)' for treating fluoroquinolone-sensitive multidrug-resistant
tuberculosis.
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Collaborators:
Asan Medical Center Dankook University Incheon St.Mary's Hospital International Tuberculosis Research Center Korea University Korean Center for Disease Control and Prevention Korean Institute of Tuberculosis National Medical Center, Seoul Pusan National University Hospital Pusan National University Yangsan Hospital Samsung Medical Center Severance Hospital SMG-SNU Boramae Medical Center Ulsan University Hospital